Practice Areas

Print PDF

12th Biosimilars Summit

January 24, 2017
Alexandria, Virginia

With the first four U.S. biosimilars approved and many more in the FDA pipeline, it is critical that pharmaceutical companies develop strategies at a business operations level to comply with evolving regulations, mitigate risk and execute long-term decisions to prepare for success. At the 12th Biosimilars Summit, industry experts spoke about the tools and strategies needed to prepare for the impending changes impacting all elements of the healthcare industry.